Abstract: The present invention provides O-nitro compounds, pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.

Abstract: The present invention provides O-nitro compounds, pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.

Abstract: The present invention provides O-nitro compounds, pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.

Abstract: The present invention provides cyclic nitro compounds, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.

Abstract: The present invention provides cyclic nitro compounds, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.

Abstract: The present invention provides cyclic nitro compounds, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.

Abstract: The present invention provides cyclic nitro compounds, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.

Abstract: This thermoplastic elastomer is present in a substantially solid state suitable for use as a binder for a propellant, explosive, and/or gas generant of a supplemental restraint system. The thermoplastic elastomer is formed from a composition including A blocks which are crystalline at temperatures below about 75° C. and B blocks which are amorphous at temperatures above about ?20° C. The A blocks are derived from oxetane derivatives and the B blocks are derived from oxiranes and derivatives thereof. The A blocks and B blocks are end-capped with a diisocyanate having a first isocyanate moiety that is substantially more reactive with the terminal groups of the blocks than the second isocyanate moiety, whereby the more reactive first isocyanate moiety is capable of reacting with the terminal groups of the blocks, leaving the less reactive second isocyanate moiety free and unreacted.

Abstract: Hexabenzylhexaazaisowurtzitane is converted to tetracetyl, dibenzyl azaisowurtzitane. The benzyl groups are removed by catalytic transfer hydrogenolysis leaving a pair of available nitrogens. The available nitrogens are acetylated, and the resulting intermediate is converted to CL-20 with a strong nitrating agent.

Abstract: This thermoplastic elastomer is present in a substantially solid state suitable for use as a binder for a propellant, explosive, and/or gas generant of a supplemental restraint system. The thermoplastic elastomer is formed from a composition including A blocks which are crystalline at temperatures below about 75° C. and B blocks which are amorphous at temperatures above about ?20° C. The A blocks are derived from oxetane derivatives and the B blocks are derived from oxiranes and derivatives thereof. The A blocks and B-blocks are end-capped with a diisocyanate having a first isocyanate moiety that is substantially more reactive with the terminal groups of the blocks than the second isocyanate moiety, whereby the more reactive first isocyanate moiety is capable of reacting with the terminal groups of the blocks, leaving the less reactive second isocyanate moiety free and unreacted.

Abstract: In this process 2,6,8,12-tetraacetyl-2,4,6,8,10,12-hexaazatetracyclo-[5.5.0.05,903,11]-dodecane (“TADH”) is subjected to nitrolysis in the presence of a mixed acid to form HNIW. The mixed acid comprises at least one nitronium ion source (preferably nitric acid) and at least one strong acid (preferably sulfuric acid) capable of generating a nitronium ion from the source. The ratio of nitronium ion source to strong acid and the amount of TADH used are selected so that, in the event that the nitrolysis reaction is carried out at 85° C., 99% nitramine conversion will occur within ten minutes.

Abstract: A thermoplastic, elastomeric block copolymer comprises at least one poly(butadiene) and at least one pair of poly(lactone) blocks flanking the poly(butadiene) block. Each poly(lactone) block is derived from a lactone having between 8 and 18 carbon atoms in the lactone ring, such as &lgr;-laurolactone and 10-hydroxyl decanoic acid lactone. Alternative methods of making these block polymers are also disclosed. In the first procedure diethyl zinc reacts with the hydroxyl end group of a butadiene polymer to form an intermediate zinc alkoxide-tipped polybutadiene which functions as the active initiating species. The laurolactone polymer then grows off the hydroxyl end groups of the butadiene to form the desired ABA block copolymer. In another related procedure for making ABA block polymers, previously prepared difunctional hydroxyl-terminated polybutadiene blocks are linked with monofunctional poly(&lgr;-laurolactone) blocks using a diisocyanate and a catalyst.

Abstract: Hexabenzylhexaazaisowurtzitane is converted to tetracetyl, dibenzyl azaisowurtzitane. The benzyl groups are removed by catalytic transfer hydrogenolysis leaving a pair of available nitrogens. The available nitrogens are acetylated, and the resulting intermediate is converted to CL-20 with a strong nitrating agent.

Abstract: A process is disclosed for producing prills comprised of ammonium dinitramide The prills can include, if desired, one or more thermal stabilizers, and processing aid(s). Solid particulate ADN is introduced into the top of a melting column, allowed to melt to form pre-prills while passing through a hot-zone ("heated zone") in the prilling column. The pre-prills are allowed to spheridize in the presence of an upwardly blown inert medium which is counter current to the path of the ADN in the prilling column. The flow is designed not to blow the ADN out of the prilling column. The rate of spheridization (prill formation) can, if desired, be accelerated by providing additional cooling, such as refrigeration, to the cooling zone in the prilling column. The ADN prills are suitable for use in propellants.

Abstract: A process for synthesizing 4,10-dinitro-2,6,8,12-tetraoxa-4,10-diazatetracyclo-[5.5.0.0.sup.5,9 0.sup.3,11 ]-dodecane ("TEX") involves combining at least one hexa-substituted piperazine derivative with a medium containing at least one nitronium anion source and at least one acid sufficiently strong to generate nitronium anions from the nitronium anion source. According to this invention, TEX yield is significantly improved by pre-heating the medium to 55.degree. C. to about 70.degree. C. and maintaining the medium from 55.degree. C. to about 70.degree. C. to permit the hexa-substituted piperazine derivative and nitronium anions to react and form the TEX. At least one NO.sub.x scavenger is added to the medium, preferably before the addition of the hexa-substituted piperazine derivative, to increase TEX yield.

Abstract: Energetic polymers and methods for their synthesis are provided. The polymers are preferably produced from cyclic ether monomers having 4 or 5 member rings. The cyclic ether monomers preferably include energetic functional groups such that a polymer formed from the monomer is itself energetic. Polymerization is catalyzed by a combination of alkylating salt and alcohol. The preferred salts are triethoxonium salts with anions such as hexafluorophosphate, hexachloroantimonate, and tetrafluoroborate. It is found that by employing the combination of selected triethoxonium salts and selected alcohols that it is possible to produce an energetic polymer with predetermined functionality and molecular weight. The salt is found to scavenge water in the reaction mixture, thus increasing control over the functionality of the final product. The salt-alcohol combination also rapidly initiates polymerization and allows higher molecular weights to be achieved.

Abstract: The invention relates to a new class of alkoxy silane compounds of the following general formula: ##STR1## wherein R is aliphatic or aromatic having from 1 to about 15 carbon atoms and R'comprises a hydrolyzable alkoxy functionality. These compounds are particularly useful as adhesion promoters when used with adhesives such as, for example, phenylethynyl terminated polyimide or polysulfide adhesives. The invention also relates to a method of synthesizing the alkoxy silane compounds defined above.

Abstract: The invention relates to a new class of alkoxy silane compounds of the following general formula: wherein R is aliphatic or aromatic having from 1 to about 15 carbon atoms and R' comprises a hydrolyzable alkoxy functionality. These compounds are particularly useful as adhesion promoters when used with adhesives such as, for example, phenylethynyl terminated polyamide or polysufide adhesives. The invention also relates to a method of synthesizing the alkoxy silane compounds defined above.

Abstract: A process of crystallizing CL-20 is disclosed. In the process, a wet CL-20 solvent/CL-20 solution is dried by azeotropic distillation of a CL-20 solvent/water azeotrope. Removal of water from the CL-20 solution permits crystallization of high density CL-20. A low density, CL-20 non-solvent is added to the resulting dry CL-20 solvent/CL-20 solution to cause precipitation of .epsilon.-polymorph CL-20. The CL-20 crystals are separated from the non-solvent and the solvent by adding sufficient water to displace the non-solvent and the solvent from the surface of the CL-20 crystals. In this fashion, the .epsilon.-polymorph CL-20 is made wet for later handling, packaging, and shipping.

Abstract: Composite propellant formulations are disclosed having a dinitramide salt oxidizer, such as ammonium dinitramide, an energetic binder, such as energetically substituted oxetane and oxirane polymers, a reactive metal, such as aluminum, and other typical propellant ingredients such as curatives and stabilizers. Propellant formulations useful for minimum smoke or reduced smoke applications, preferably include little or no reactive metal. The disclosed propellant formulations are able to combust the reactive metal efficiently, possess high burn rates, and produce little or no HCl exhaust gases.